Strong topline growth masks margin collapse and lithium setback
Amara Raja grew revenue 24% but missed its EBITDA margin target by 3.4 percentage points. The miss reveals structural cost pressures and execution risks in its pivot to lithium-ion.
₹4,215 Cr
+23.9% YoY
9.6%
-3.4pp vs 13–14% EBITDA target
₹191 Cr
+15.9% YoY | -39.3% QoQ
Amara Raja's Q1 result looks strong on the headline: revenue up 24% and profit up 16% year-on-year. But that profit jump masks a sharper truth—a sequential collapse of 39% from the prior quarter, driven by raw material inflation, warranty provisions, and strategic spending that management flagged as temporary. More tellingly, operating margin landed at 9.6%, missing the company's own prior guidance of 13–14% EBITDA by 3.4 percentage points. Management issued no revised margin target on this call. It effectively withdrew the prior promise. That withdrawal is the quarter's real story: something changed, and it matters more than the top-line beat.
Where the profit went—and why margins collapsed
The margin miss tracks to four overlapping pressures. Raw material inflation (sulfuric acid, poly, alloys, tin) continues unabated; 3% price hikes in Q1 plus planned 2–3% more are only a partial offset. B2B customers resisted price increases more than B2C buyers did, delaying the full pass-through. Strategic spending—brand campaigns (₹35 Cr in Q1), the Amaron Assist pilot, Factory of the Future capex-like debottlenecking—absorbed another ~1 pp of margin. Finally, warranty provisions hit the profit-and-loss as a one-time charge on the entire unexpired product base due to rising product costs. Management acknowledged these hits as temporary in their case (brand, initiatives) but structural in others (freight, commodity inflation, warranty). None of this adds confidence that a quick snap-back to 13–14% is coming.
Price hikes (3% Q1, 2–3% more) will offset cost inflation
OverstatedFull-year margin recovery still hedged on commodity stability. B2B pass-through lags B2C. Structural pressures (freight, warranty) persist.
16 GW lithium capacity by FY30 (fixed target)
ContradictedNow demand-contingent. Management: 'the milestone can change.' Pursuing 15–20% market share instead.
Reasonable order book visibility for BESS; 5 GW ramp in 6 months
UnverifiedNo customer names, contract values, or off-take agreements disclosed. Claim relies on 'order book we are seeing.'
Lead-acid 22% growth; domestic market resilient
SupportedAftermarket +15% volume, OEM +24–35%, home energy +60%. But exports -20% YoY (Middle East freight). Supporting claim.
What changed on this call
Three material reversals. (1) The 16 GW FY30 lithium target is now demand-contingent. Prior guidance positioned this as a fixed ambition (₹9,000 Cr capex across 5 facilities); management now frames it as flexible based on market demand signals. The implicit message: capacity expansion may undershoot 16 GW. (2) The Gotion NMC partnership failed. The company pivoted to internal R&D ('plan B'), acknowledging that tech support from external sources must be augmented with homegrown capability. This extends timelines and raises execution risk. (3) The 13–14% EBITDA margin target has been abandoned. No new target was offered. This is not a restatement of the old one or a temporary walk-down; it's an outright retreat. These moves signal management's recalibration: lithium is harder than assumed, and margin recovery will take longer.
Lead-acid 22% growth driven by real demand (aftermarket +15% volume, OEM +24–35%, home energy +60%)
New Energy revenue ₹209 Cr (+70%); telecom lithium packs +50%, maintaining 60% combined market share
Capex on track: ₹1,700 Cr FY27 (₹1.3 Cr to New Energy); Giga 1 cell plant H1 FY28, BESS 10 GWh facility on timeline
Customer qualification plant live (July 2026); NMC 2 GWh equipment due Q3 delivery for OEM testing
Stock up 8% day 1 post-result, +5.57% by day 3; market receptive to growth narrative
OPM 9.6% misses 13–14% prior target by 3.4 pp; no recovery timeline articulated
Raw material inflation (poly, sulfuric acid, alloys) structural; price hikes only partial pass-through
Warranty provisions (one-time charge on entire unexpired product base) signal embedded cost pressure
Export volume -20% YoY (Middle East freight)—recovery contingent on geopolitical normalization
Gotion partnership failed; 16 GW lithium target now demand-contingent; LFP development timeline withheld
BESS 'reasonable order book' unquantified; margins only 5–8% vs. 14–15% for lead-acid
PAT -39.3% QoQ (from ~₹315 Cr Q4 to ₹191 Cr Q1); sequential earnings volatility elevated
Raw material inflation persists; price hikes insufficient to offset
HighSulfuric acid, poly, alloys, tin rising unabated. 3% Q1 hike + 2–3% planned insufficient if commodity inflation continues. B2B pricing power weak vs. B2C. Margin recovery depends on commodity stabilization—out of management control.
Lithium execution at risk; de-guidance signals loss of confidence
HighGotion partnership failed; 16 GW FY30 target now demand-contingent; LFP tech timeline unknown. ₹1.3 Cr FY27 capex on unproven tech. Profitability in lithium (5–8% margins) far below lead-acid (14–15%), ensuring blended margin compression as mix shifts.
Export recovery contingent on geopolitical normalization
MediumAutomotive exports fell 20% YoY due to Middle East freight costs and alternate sea routes. Management expects recovery 'as normalcy gets restored'—a hope, not a plan. Any delay extends lead-acid volume headwinds.
BESS ramp unproven; order book opaque; margins structurally lower
Medium'Reasonable order book visibility' mentioned; no customer names, contract values, or off-take agreements disclosed. Capex ₹250–300 Cr for 10 GWh, but margins only 5–8% vs. 14–15% for lead-acid. Demand disappointment would crater returns.
Sequential profit volatility; Q1 PAT -39.3% QoQ signals deteriorating quality
MediumProfit collapsed from ~₹315 Cr (Q4) to ₹191 Cr (Q1). Warranty provisions and strategic spending explain part of it, but suggests earnings quality is fragile under cost pressures. Recurrence risk high if commodity inflation or geopolitical stress persists.
1 · Q2 commodity price trajectory & pricing power
If raw material inflation persists, management must take further price hikes. Monitor B2B customer resistance; if customers push back, margin recovery stalls. The company has guided 2–3% more hikes coming; sufficiency will become clear in Q2.
2 · Export volume recovery timing (Middle East sea routes)
Automotive exports fell 20% YoY. Management expects recovery as alternate sea routes normalize, but timing is opaque. Q2 export volumes will signal whether this is a near-term catalyst or another quarter of delay.
3 · Lithium cell customer qualification progress
Customer qualification plant live (July). NMC 2 GWh equipment due Q3; OEM testing to follow. Clear milestones (first orders, homologation completion, LFP timeline) would de-risk the lithium narrative. Absence of clarity will deepen doubt on execution.
4 · BESS facility commissioning & hard order visibility
Expected commissioning for 10 GWh BESS facility per timelines. Management expects 5 GW utilization within 6 months of commissioning. Hard evidence of customer commitments (names, contract values) will validate the 'reasonable order book' claim or expose it as vague.
5 · Margin guidance re-issuance (critical)
Management withdrew the 13–14% EBITDA margin target this call. At the next update, expect heavy analyst pressure for a new target. If re-guided to 10–11%, expect structural margin compression to be confirmed. If re-guided to 12%+, that assumes commodity deflation and flawless execution—higher risk, higher visibility reward.
How the street is positioned. The stock ran 8% on day 1 post-result announcement (Aug 10) and held gains, up 5.57% by day 3. This is a bullish reception of a mixed quarter—the market is pricing in topline momentum and long-term new energy optionality, but largely forgiving the margin miss as temporary. At ₹949, the stock sits above its 20-day SMA (₹914.6), 50-day SMA (₹877.28), and 200-day SMA (₹871.29), confirming an intact uptrend. It sits 7.19% below its all-time high of ₹1,022.5, but 41% above its 52-week low of ₹671.45—a recovery from weakness, not an overbought extreme. RSI at 64.3 is neutral (neither overbought nor oversold). Domestic institutions (DII) trimmed 1.65 pp of ownership in the quarter (now 15.3%), signaling slight profit-taking. Foreign institutions (FII) added marginally (+0.03 pp, now 17.34%), consistent with accumulation at lower prices. The market's verdict: growth is real, but margin recovery is not yet priced in—the pop reflects confidence in the topline, not certainty about profitability.
Amara Raja delivered a quarter of topline strength and strategic optionality, but revealed uncomfortable truths about profitability. The 3.4 pp margin miss, combined with lithium de-guidance and Gotion's failure, signals that management's confidence in both near-term margins and long-term execution has dimmed. The lead-acid business remains resilient (22% growth, domestic demand intact), but the company is in a race against time: can it stabilize commodity-driven cost inflation, prove lithium-cell economics at scale, and ramp BESS to offset structural margin compression—all while funding ₹1.3 Cr/year in new energy capex? The market is betting yes; holders should demand quarterly proof.
The number to track from here is operating margin. If Q2 delivers ≥10.5%, management's 'temporary cost' narrative holds and commodity inflation is easing. If Q2 dips below 9.5%, the structural margin story wins and the 13–14% target is forgotten. Rating: Hold with a bias to accumulate on further weakness; the risk/reward improves only when margin recovery becomes visible, not merely promised.
Lithium Ramp Meets Lead-Acid Headwinds—Can Margin Resilience Hold?
With a ₹500 Cr Li-ion qualification plant now live and EV demand accelerating, Amara Raja faces a pivotal quarter: how quickly will the new capacity offset commodity price pressure in its legacy lead-acid business?
Amara Raja Batteries enters Q1 FY-2027 at an inflection point. After a decade of lead-acid market dominance, the company commissioned a ₹500 Cr customer-qualification plant (CQP) for lithium-ion batteries on July 15—the biggest capex bet in its history. The timing is deliberate: as lead-acid commodity prices face cyclical pressure and global automotive majors accelerate EV transitions, the company must prove it can scale li-ion volumes fast enough to offset margin compression in legacy channels. This quarter will show early evidence of that ramp and whether legacy volumes hold.
What to Expect
~₹3,300–3,400 Cr
Q4 FY26 (latest) revenue ₹3,460 Cr; Q1 typically flat to +2% seasonal; expect run-rate maintenance or slight growth if LAB holds volume
16–17.5%
Q4 FY26 showed strong recovery (consolidated net profit +94.5% YoY); watch for LAB margin sustainability amid input cost pressure
₹540–580 Cr
FY26 PAT ₹1,307 Cr; quarterly run-rate ~₹327 Cr; watch tax impact
~₹13–14
FY26 EPS ₹53.02; no stock splits announced; quarterly ~₹13.25
A strong Q1 would show: (1) revenue holding at or above ₹3,300 Cr despite lead-acid commodity headwinds (implying volume resilience or price recovery); (2) operating margin not collapsing below 16% (proof that li-ion mix is offsetting lag); (3) management commentary on li-ion sample pull-through timeline, OEM design-win pipeline, and expected CQP utilization by year-end. A weak Q1 would flag: (1) revenue below ₹3,100 Cr and falling YoY; (2) margin compression below 15%; (3) silence or vagueness on li-ion ramp, CQP delays, or OEM push-back on qualification timelines.
On Track?
Management has not yet issued formal FY-2027 guidance, but the FY26 trajectory and capex announcements point to a growth-with-resilience thesis. FY26 revenue grew 9% to ₹13,549 Cr; PAT grew 16% (outpacing revenue, suggesting margin expansion). The immediate driver is scale and mix—li-ion is higher-margin than lead-acid, but only if volumes materialize. The ₹500 Cr CQP is a multi-year investment; Q1 is proof-of-concept. Watch for management to outline (1) expected li-ion contribution to full-year FY27 revenue (target %), (2) when CQP hits 50% utilization, and (3) confidence in 10–15% revenue CAGR over the next 3 years as EV penetration accelerates.
Street View
Since Last Quarter
Jul 15
₹500 Cr Li-Ion CQP Commissioned (Telangana)
Positive—capex milestone hit; customer qualification underway. Sets stage for ramp this FY.
Jul 18
APPCB Closure Orders Revoked
Positive—regulatory risk cleared for Karakambadi & Nunegundlapalle plants. No operational headwind going forward.
Jul 17
FY26 Annual Report & AGM Notice (Aug 10)
Routine—41st AGM on Aug 10 (same day as Q1 result); BRSR filed. Final dividend ₹5.20 + interim ₹5.40 = ₹10.60 total.
Jul 27
GST Penalty: Amara Raja Energy (Subsidiary) ₹13.3 L
Immaterial—minor penalty on subsidiary; no operational impact. Shows compliance tightening.
No insider buying or pledges flagged in recent months. Promoter holding steady at 32.86%; FII stake has drifted down slightly (19.39% → 17.31% QoQ) but remains healthy. The revocation of APPCB closure orders eliminates a tail risk that had spooked some investors. Notably, the AGM is scheduled on the same day as Q1 results (Aug 10), which will compress the management commentary window—watch for a call or pre-AGM guidance note.
What to Watch on Result Day
1 · Lead-Acid Volume & Price Trajectory
The lifeblood of current profit. Management must clarify: Have domestic lead-acid volumes held flat or grown YoY? What is the pricing environment (recovered, flat, or under pressure)? Lead-acid is 70%+ of revenue; the narrative flips bearish if volumes drop >5% or ASPs fall >3%.
2 · Li-Ion Ramp: Samples → Orders → Revenue
CQP is now live. How many OEM design-wins are in qualification? Expected revenue contribution from li-ion in Q1? Management should guide on (a) expected li-ion revenue as % of FY27 (target 5–10%?), (b) CQP utilization rate by Q4, (c) which OEMs are closest to production. Silence here signals delays.
3 · Margin Guidance & Capex Plan for FY27
With li-ion mix improving but lead-acid under pressure, can operating margin hold above 17%? Will CQP require additional capex, or is ₹500 Cr the main hurdle? A guided margin band (e.g., 17–18%) for FY27 would anchor confidence. Lack of visibility here keeps the stock in consolidation mode.
Amara Raja Batteries is in the middle of a decade-long transition: from a pure-play lead-acid battery company to a diversified player with a credible li-ion footprint. Q1 FY-2027 is the first full quarter showcasing that pivot—the ₹500 Cr CQP is operational, customer samples are in flight, and the company faces a maturing EV market ready to pull volume. The test: can margins hold as mix shifts, and is the ramp real or just hope? Revenue should hold firm (~₹3,300 Cr), margins should not compress below 16%, and management must articulate clear li-ion milestones. If all three are met, confidence in the long-term story (20%+ EPS CAGR over 3 years) reinforces; if margins crack or li-ion silence persists, the narrative reverts to a cyclical battery play vulnerable to commodity swings. Watch the Q1 print closely.
Strong revenue growth overshadowed by 3.4pp margin miss
The verdict, the claims that held up, the sharpest analyst exchanges, and the risks — the earnings call, decoded from the transcript.
Hold
confidence 6/10
Grade B
Hit Q1 revenue, missed margin guidance. Explanations (brand, efficiency investments) are partly temporary but raw material inflation is structural. Lithium path uncertain.
Cautiously Optimistic
next 1–2 quarters
Optimistic
multi-year
Strong 24% revenue growth driven by lead-acid and home energy demand, but consolidated margin crushed to 9.6%, missing 13-14% EBITDA target by 3.4 pp. Raw material inflation, capex-lite Factory of the Future costs, and brand spend explain ~1 pp; structural pressures (freight, warranty provision) persist. New Energy capex is aggressive (₹1.3 Cr FY27) but littered with execution risks: Gotion partnership failed, 16 GW target walked back, LFP technology timeline unknown.
₹4215 Cr
Revenue · +23.9% YoY₹190.9 Cr
Reported PAT · +15.9% YoYCompressing
Margins · vs guidance: OverstatedDid the claims hold up?
Revenue growth 24% consolidated, 22% lead-acid
METDelivered ₹4,214.5 Cr (+23.9% YoY), lead-acid ~₹4,004 Cr
EBITDA margins target 13-14%, Q1 10.1% standalone
MISSDelivered OPM 9.6% consolidated, down 0.5pp due to New Energy costs
3% price hike in Q1 offset cost pressures, 2-3% more coming
OVERSTATEDQ1 delivered 4.5% NPM vs 13-14% target; full recovery remains hedged on commodity stability
16 GW by FY30 lithium capacity target
MISSNow demand-contingent; management says 'milestone can change', pursuing 15-20% market share instead
Reasonable order book visibility for BESS, 5 GW ramp in 6 months
UnverifiedNo customer names or hard contract values disclosed; claim relies on 'order book we are seeing'
Earnings quality
What changed since the last call
16 GW lithium target de-guided
DowngradePrior FY30 ambition (₹9,000 Cr capex) now demand-contingent; management reframed as 15-20% market share pursuit. Implies capacity additions below 16 GW possible based on demand signals.
Gotion partnership abandoned
WithdrawnNMC tie-up 'did not go through as planned.' Pivoted to internal R&D + 'plan B' (teams improving cells beyond partner tech). De-risks tech but extends timelines.
EBITDA margin guidance implicitly withdrawn
NeutralNo new EBITDA margin target issued this call. Q1 delivered 9.6% vs prior 13-14%. Management attributes miss to temporary costs (brand, initiatives) + structural headwinds (raw materials, warranty), but has not re-guided.
Lithium capex lock-in maintained
NeutralFY27 capex ₹1,700 Cr (₹1,300 Cr New Energy) reaffirmed within prior ₹1,500-1,700 Cr band. But scope (16 GW → demand-driven) is now flexible.
Export recovery hedged on geopolitics
DowngradeQ1 automotive exports -20% YoY due to Middle East freight costs (alternate sea routes expensive). Management says recovery dependent on 'normalcy' + 'how geopolitical situation evolves' — contingent, not assured.
The Q&A
Light pressure overall. Analysts asked specific questions on capex, margins, BESS units/asset turns, lithium timelines; management answered with numbers but hedged on LFP tech (no timeline), BESS order book (only 'reasonable'), and 16 GW (now demand-contingent). No analyst challenged margin miss aggressively; most focused on forward strategy. Management held firm on new energy capex despite margin pressure.
Margin recovery timeline — Kapil Singh, Nomura
Answered3% Q1, 2-3% this month. Raw materials (poly, sulfuric acid, alloys) still rising. B2B pass-through delayed vs B2C. If prices stabilize, 2-3% more hikes should suffice; if not, further increases needed.
Other expenses sustainability — Kapil Singh, Nomura
AnsweredBrand & Amaron Assist pilot temporary. Factory of the Future capex-like (cannot capitalize). Warranty provisions one-time hit on P&L. Freight & fuel may recur due to geopolitics. In 2-3 quarters, brand/efficiency spending should normalize.
BESS business model — Kapil Singh, Nomura
PartialCapex ₹250-300 Cr, 10 GWh. Asset turns higher but not quantified. Margins 5%-6% to 7%-8% (pack-like, improving with localization). Advantage: customer relationships, eventual cell localization via government support.
NMC equipment delivery — Vibhav Zutshi, JPMorgan
AnsweredDue for delivery in Q3.
BESS ramp & customer commitments — Vibhav Zutshi, JPMorgan
PartialReasonable order book visibility with major EPC players. Within 6 months of commissioning, expect 5 GW utilization based on market demand for solar energy storage. Thereafter, depends on market.
Other expenses stabilization — Vibhav Zutshi, JPMorgan
AnsweredOnce initiatives (brand, debottlenecking) complete, will see reducing trend. But freight (higher fuel) & warranty (higher raw material) will persist until commodity prices stabilize. Other costs (employee, admin) under moderation.
Export recovery path — Raghunandhan, Nuvama
AnsweredAutomotive exports -20% YoY due to Middle East freight. Expecting recovery in subsequent quarters as sea routes normalize. UPS +10%, telecom lithium +50%, other industrial 5-6%.
BESS asset economics — Raghunandhan, Nuvama
DodgedWon't quantify asset turns yet; depends on product mix. Economic metrics likely in line with pack business. Picture will clear after 6 months of operation.
Lithium cell qualification timeline — Raghunandhan, Nuvama
Partial2170 NMC B samples in production. OEM testing will be extensive; C sample & homologation take time. Storage customers faster than EV. LFP can be tested at facility.
Gotion partnership & LFP tech — Shubham, Investec
AnsweredGotion did not go through as planned. NMC: tech absorbed, team improved beyond partner input. LFP: plan B in place, no new partnership yet. Case-by-case basis; geopolitical constraints rule out broad China arrangements.
16 GW capacity target revision — Shubham, Investec
Answered16 GW was initial strategy (₹9,000 Cr, market size 100-130 GW). Now demand-driven; capacity/timing can change. Strategic direction 15-20% market share still intact. Redundant capacity taxing, so demand-aligned expansion.
Lead-acid full-year growth — Rishi Vora, Kotak
AnsweredDomestic aftermarket: 2-wheeler lower double-digit, 4-wheeler 7-8%. Full-year lead-acid (incl. industrial, exports) estimate 9-10% (industry view, not formal guidance). EV penetration will moderate later.
BESS working capital — Rishi Vora, Kotak
PartialDepends on customer mix & credit terms. Estimate ~90-100 day cash conversion cycle (pack business analog). Not certain without knowing cell procurement credit arrangements.
LFP development timeline & R&D investment — Rishi Vora, Kotak
PartialPlan B in place. Teams working on product development. ₹100-150 Cr R&D spend this year. Premature to commit specific timeline; depends on development program for cell type. Industrialization key.
Lithium competition & price discipline — Deepesh Joshi, Indira
Answered3-4 player market expected domestically. Won't compete inter-India; will compete with China imports. Price gap 15-20% vs China due to supply chain maturity. No inter-India price war expected.
Capex funding strategy — Deepesh Joshi, Indira
AnsweredMultiple options. Holding company cash flow ₹700-800 Cr post-tax post-dividend. Risk capital ₹2,500 Cr covers 5 facilities. Future capex: need to explore options based on business cases.
NMC technology maturity & R&D needs — Kapil Singh, Nomura
AnsweredSpeed of change has moderated. Capex should serve product for reasonable time. Need fungibility between products. R&D effort cannot be reduced; teams must continue developing for market requirements.
Raw material supply risk — Kapil Singh, Nomura
PartialNot aware of specific restrictions on battery cathode/anode. Processed material still flowing. Broader supply chain localization a long-term industry goal. Will monitor; no current barriers noted.
Guidance
Lead-acid volume growth ~9-10% (industry estimate, not formal guidance)
MediumDomestic aftermarket 7-8% (4-wheeler) to lower double-digit (2-wheeler). Will improve once international recovery kicks in. EV penetration will moderate later.
New Energy revenue scaling from ₹209 Cr Q1 baseline (70% growth)
MediumCustomer qualification plant live (July). Ramp dependent on OEM/storage customer acceptance. EV cell orders pending homologation completion; storage (LFP) faster path.
No new EBITDA margin target provided (prior 13-14% implicitly abandoned)
LowQ1 delivered 9.6%. Management cites temporary cost pressures (brand, initiatives, ~1 pp), structural headwinds (raw materials, warranty, ~2-3 pp). Recovery tied to commodity price stabilization + initiative completion.
BESS operating margin 5%-6% to 7%-8% (pack business analog, improving with localization)
MediumConservative case 5%-6%, upside 7%-8%. Asset turns higher than pack business but not quantified. Margins expand with local content & scale.
FY27 capex ₹1,700 Cr (₹1,300 Cr New Energy, rest lead-acid + recycling)
HighQ1 spent ₹450 Cr. Giga 1 cell plant (H1 FY28), BESS 10 GWh, E Positive facility, 2 GWh NMC line. Capex outlay 'majorly towards upcoming facilities.'
Risks the call surfaced
Raw material cost
HighSulfuric acid, poly, alloys rising substantially. 3% Q1 hike & 2-3% planned insufficient if inflation continues. B2B segment delayed pass-through vs B2C. Warranty provisions hit P&L for entire unexpired product base.
Export market headwind
MediumAutomotive exports -20% YoY primarily Middle East due to expensive alternate sea routes. Recovery assumed but contingent on geopolitical normalization. Reversal could extend margin pressure.
Lithium technology execution
HighGotion tie-up failed; NMC tech absorbed internally (risk of unproven capability). LFP development has no committed timeline ('premature to comment'). 16 GW FY30 target de-guided to demand-contingent. R&D spend ₹100-150 Cr/year ongoing, with no path to profitability visible.
Lithium competitive intensity
HighPrice gap vs China 15-20% due to nascent Indian supply chain. 3-4 domestic players expected; no inter-India price war anticipated but imports will pressure. Cathode material fully China-dependent; localization aspirational (long-term).
BESS market ramp unproven
MediumOrder book described as 'reasonable' but not quantified. Management expects 5 GW utilization within 6 months; thereafter depends on market. Capex ₹250-300 Cr; margins 5-8%. If demand disappoints, returns could lag expectations.
Management
Score 6/10. Candid on cost breakdowns & segment performance; hedgy on lithium timelines, BESS order book ('reasonable' not quantified), LFP tech ('premature to comment'). Gotion failure acknowledged. Margin miss explained but recovery timeline uncertain. Hit Q1 revenue ₹4,215 Cr (+23.9% YoY). Missed EBITDA margin target (9.6% vs 13-14%). Lead-acid growth on track; new energy capex progressing but lithium partnerships unstable (Gotion failed). Track record: promises delivered on capex timelines, but profitability lagging.
1 · Q2 FY27 (Sep 2026)
Additional 2-3% price hikes rolled out; raw material inflation trajectory critical
2 · Q3 FY27 (Dec 2026)
2 GWh NMC equipment delivery; OEM testing initiation for lithium cells
3 · H1 FY28 (Jan-Mar 2027)
Giga 1 cell plant commercialization; first revenue from lithium cells
New Energy capex is aggressive (₹1.3 Cr FY27) but littered with execution risks: Gotion partnership failed, 16 GW target walked back, LFP technology timeline unknown.
Amara Raja Q1FY27: PAT +16% YoY as margins compress despite 24% revenue growth
PAT +15.86% YoY · revenue +23.92% · margins compressing · miss vs street
₹4,214.54 Cr
+23.92% YoY
₹190.94 Cr
+15.86% YoY
4.51%
-0.3pp YoY
₹10.43
Amara Raja Energy & Mobility's consolidated (primary basis) revenue from operations rose 23.9% YoY to ₹4,214.5 Cr in Q1 FY27 (quarter ended June 30, 2026), while consolidated PAT grew 15.9% YoY to ₹190.9 Cr from ₹164.8 Cr a year ago — profit growth trailing revenue growth, the first marker of margin pressure. The print falls short of Street PAT expectations: a pre-result preview (Univest) had pegged Q1 FY27 PAT at ₹218-277 Cr against a revenue estimate of ₹3,671-4,224 Cr — revenue landed near the top of that range but PAT missed the low end by roughly ₹27 Cr. Standalone PAT grew just 4.5% YoY (₹202.8 Cr vs ₹194.0 Cr) on 20.6% revenue growth, a materially slower profit trajectory than the consolidated number — the gap traces to subsidiary contribution, chiefly a narrower New Energy segment loss and higher other income at the group level.
Q1 FY-2027 vs prior quarters
Both bases show margin compression. Consolidated operating margin (PBT after exceptional items plus finance cost and depreciation, less other income, over revenue from operations) came in at 9.6% versus 10.7% a year ago; net margin on total income slipped to 4.5% from 4.8%. Standalone operating margin fell to 10.1% from 11.5%. This sits well below management's own target of 13-14% EBITDA margin for the lead-acid business via efficiency gains and price increases — cost pressure in lead-acid clearly has not yet been offset by the pricing actions management flagged on the last call. Segment-wise, lead-acid batteries revenue grew a strong 22.1% YoY to ₹4,005.2 Cr — ahead of the guided mid-to-high single-digit growth — but segment result margin was a comparatively thin 6.7% (₹269.6 Cr on ₹4,005.2 Cr), pointing to the same cost/pricing squeeze. New Energy revenue was ₹209.3 Cr with the segment loss narrowing to ₹22.1 Cr from ₹35.2 Cr YoY — moving toward breakeven but still a drag.
The stock went into the print at ₹911, up 2.5% over the past month of trading.
For context: revenue is at a 6-quarter high.
Management provided guidance for a strong FY27, expecting mid-to-high single-digit growth in the lead-acid battery segment, driven by both domestic and international markets. The company plans significant capex of INR1,500-1,700 crores for the upcoming year, with the majority allocated to the New Energy business, signa
— This quarter: missed
On capex, the company infused a further ₹150 Cr into wholly-owned subsidiary Amara Raja Advanced Cell Technologies (ARACT) this quarter, taking cumulative investment there to ₹1,650 Cr — an early, sizeable step against the ₹1,500-1,700 Cr FY27 capex guidance skewed toward New Energy. Two other developments this quarter tie to the print: the Andhra Pradesh Pollution Control Board revoked its 2021 closure orders on the Karakambadi and Nunegundlapalli plants on July 18, 2026, and the company withdrew the related writ petitions on August 6, 2026 — removing a long-standing regulatory overhang without any operational disruption visible in the numbers. A ₹13.3 lakh GST penalty paid in July is immaterial to the print. No management press release or call transcript was available to cross-check management's own framing of the quarter against these figures.
W1
Whether lead-acid pricing/efficiency actions close the gap to management's 13-14% EBITDA margin target — consolidated OPM was 9.6% this quarter
W2
New Energy segment's path to breakeven and toward management's guided 6-7% BESS margin — segment loss was ₹22.1 Cr this quarter, narrowed from ₹35.2 Cr YoY
W3
Pace of FY27 capex deployment against the ₹1,500-1,700 Cr guidance — ₹150 Cr already committed to ARACT in Q1 alone
No exceptional items in the current or year-ago quarter (clean YoY), but the QoQ comparator (Q4 FY26) included a ₹181.15 Cr pre-tax exceptional gain on both standalone and consolidated statements, distorting raw QoQ PAT comparison; figures native in ₹ Crore, no conversion needed; minor OCR artifacts in subtotal text did not affect verified totals.